50 of the Top 250 law firms use our Products every day
Sirna
Therapeutics Shareholders Approve Acquisition by Merck &
Co.
SAN FRANCISCO,
CA, Dec. 28, 2006 — Sirna Therapeutics, Inc. (NASDAQ: RNAI)
announced that Sirna shareholders approved the acquisition of Sirna
by Merck & Co., Inc. at a special meeting today. The
shareholder vote is a necessary condition for the completion of the
acquisition of Sirna, a leader in the discovery and development of
RNAi-based therapeutics. The acquisition is expected to close as
soon as reasonably practicable, subject to satisfaction of
customary closing conditions.
About Sirna
Therapeutics, Inc.
Sirna Therapeutics is a clinical-stage biotechnology company
developing RNAi-based therapies for serious diseases and
conditions, including age-related macular degeneration (AMD),
hepatitis C, dermatology, asthma, respiratory syncytial virus
(RSV) and Huntington’s disease. Sirna Therapeutics
completed its Phase I clinical trial for Sirna-027 in AMD in 2005
and with its strategic partner, Allergan, Inc., is moving Sirna-027
forward into Phase II clinical trials. Sirna has selected a
clinical ca
|
